REFERENCES

1. Lal S.S., Sukla Y., Singh A., Andriyas E.A and Lal A.M. Hyperuricemia, high serum urea and hypoproteinemia are the risk factor for diabetes. Asian Journal of Medical Sciences. 2009; 1: 33-34.
2. Doss A., Palaniswamy M., Angayarkanni J and Dhanabalan, R. Antidiabetic activity of water extract of Solanumtrilobatum (Linn.) in alloxan-induced diabetes in rats. African Journal of Biotechnology. 2009; 8: 5562-5564.
3. Asaduzzaman, Akhtalz A., Islam A., Khan R.I., Anisuzzamanz and Ahmed M. Evaluation of antidiabetic, antihyperlipidemic and hepatoprotective effects of Allium Sativum (Linn.) in alloxan induced diabetic rats. Bangladesh Pharmaceutical Journal. 2010; 13: 28-33.
4. Mehta S.R., Kashyap A.S and Das C.S. Diabetes mellitus in India: the modern scourge. Medical Journal Armed Forces India. 2009; 65: 50-54.
5. Sies H. What is oxidative stress? In: Keaney JF Junior ed. Oxidative Stress and Vascular Disease. Boston: Kluwer Academic Publishers, 2000: 1-8.
6. Gumieniczek A, Hopkala H, Wojtowich Z, Nikolajuk J. Changes in antioxidant status of heart muscle tissue in experimental diabetes in rabbits. ActaBiochim Pol. 2002; 49: 529-535.
7. Bonnefont-Rousselot D, Bastard J.P, Jaudon M.C, Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab. 2000; 26: 163-176.
8. Betteridge DJ. What is oxidative stress? Metabolism 2000; 49: 3-8.
9. Reusch J.E and Draznin B.B. Atherosclerosis in diabetes and insulin resistance. Diabetes ObesMetab. 2007; 9:455–463.
10. Saydah S.H, Fradkin J and Cowie C.C. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-342.
11. Stratton I.M. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000; 321:405-412.
12. Turner R.C. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS 23), BMJ. 1998; 316:823-828.
13. Farmer JA. Diabetic dyslipidemia and atherosclerosis: evidence from clinical trials. CurrDiab Rep. 2008; 8:71-77.
14. Goff D.C JR. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007; 99:4-20.
15. Brunzell JD. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation, Diabetes Care. 2008; 31:811-822.
16. American Diabetes Association: Standards of medical care in diabetes, Diabetes Care. 2009; 32 (1):13-61.
17. Stamler J, Vaccaro O, Neaton J.D and Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993; 16:434-444.
18. Grundy SM. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation. 2004; 110:227-239.
19. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of Glimepride to metformin monotherapy in type 2 diabetic patients. Diabet Med. 2001 Oct; 18(10):828-34. \
20. Md. AkramMinhaj, MdWaris. Effect of Interaction Between Metformin And Glimiperide On Glycosylated Haemoglobin And Lipid Profile In Stress Induced Type 2 DM. Journal of Drug Delivery and Therapeutics; 2013, 3(3), 81-84.